Literature DB >> 32880934

The importance of data source in prescription drug monitoring program research.

Jill R Horwitz1,2, Corey Davis3, Lynn McClelland4, Rebecca Fordon4, Ellen Meara2,4.   

Abstract

OBJECTIVE: To develop a legal research protocol for identifying various measures of prescription drug monitoring program (PDMP) start dates, apply the protocol to create a useable PDMP database, and test whether the different legal databases that are meant to contain the same information produce divergent results when used in an illustrative empirical exercise. DATA SOURCES: Original research from state statutes, regulations, policy statements, and interviews; alternative PDMP data from the National Alliance for Model State Drug Laws and Prescription Drug Abuse Policy System; claims from a 40 percent random sample of Medicare beneficiaries, 2006-2014. STUDY
DESIGN: Collaborative research effort among a group of lawyers to develop protocol. Legal research to produce an original database of dates state PDMP laws: (a) were enacted, (b) became operational, and (c) required query before prescribing controlled substances. Descriptive analyses characterize differences in dates of enactment, operation, and must query requirements. Regression analyses estimating, for each beneficiary annually any opioid prescription received in a calendar year, among other measures. Estimates conducted on under age 65 and full Medicare population. DATA COLLECTION/EXTRACTION
METHODS: PDMP legal databases were linked to annual Medicare claims. PRINCIPAL
FINDINGS: An original database differs from commonly used, publicly available data. Outcomes tested depend on the measure of PDMP date used and differ by data source. Must-query laws show the largest effects among all the laws tested.
CONCLUSIONS: Data choices likely have had large consequences for study results and may explain contradictory outcomes in prior research. Researchers must understand and report protocol for dates used in PDMP research to ensure that results are internally consistent and verifiable.
© 2020 Health Research and Educational Trust.

Entities:  

Keywords:  Medicare; legal epidemiology; opioids; policy evaluation; prescribing behavior; regulation

Mesh:

Year:  2020        PMID: 32880934      PMCID: PMC7968938          DOI: 10.1111/1475-6773.13548

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  13 in total

1.  Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations.

Authors:  M Weintraub; S Singh; L Byrne; K Maharaj; L Guttmacher
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

2.  Commentary on Pardo (2017) and Moyo et al. (2017): Much still unknown about prescription drug monitoring programs.

Authors:  Corey S Davis
Journal:  Addiction       Date:  2017-10       Impact factor: 6.526

3.  Effect of a triplicate prescription law on prescribing of Schedule II drugs.

Authors:  K A Sigler; B G Guernsey; N B Ingrim; A S Buesing; J A Hokanson; E Galvan; W H Doutré
Journal:  Am J Hosp Pharm       Date:  1984-01

4.  Prescription opioid use among disabled Medicare beneficiaries: intensity, trends, and regional variation.

Authors:  Nancy E Morden; Jeffrey C Munson; Carrie H Colla; Jonathan S Skinner; Julie P W Bynum; Weiping Zhou; Ellen Meara
Journal:  Med Care       Date:  2014-09       Impact factor: 2.983

5.  Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses: A Systematic Review.

Authors:  David S Fink; Julia P Schleimer; Aaron Sarvet; Kiran K Grover; Chris Delcher; Alvaro Castillo-Carniglia; June H Kim; Ariadne E Rivera-Aguirre; Stephen G Henry; Silvia S Martins; Magdalena Cerdá
Journal:  Ann Intern Med       Date:  2018-05-08       Impact factor: 25.391

6.  Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions.

Authors:  Richard A Deyo; Jessica M Irvine; Lisa M Millet; Todd Beran; Nicole O'Kane; Dagan A Wright; Dennis McCarty
Journal:  Health Aff (Millwood)       Date:  2013-02-13       Impact factor: 6.301

7.  Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.

Authors:  Yuhua Bao; Yijun Pan; Aryn Taylor; Sharmini Radakrishnan; Feijun Luo; Harold Alan Pincus; Bruce R Schackman
Journal:  Health Aff (Millwood)       Date:  2016-06-01       Impact factor: 6.301

8.  Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates.

Authors:  Stephen W Patrick; Carrie E Fry; Timothy F Jones; Melinda B Buntin
Journal:  Health Aff (Millwood)       Date:  2016-06-22       Impact factor: 6.301

Review 9.  A Transdisciplinary Approach to Public Health Law: The Emerging Practice of Legal Epidemiology.

Authors:  Scott Burris; Marice Ashe; Donna Levin; Matthew Penn; Michelle Larkin
Journal:  Annu Rev Public Health       Date:  2015-11-30       Impact factor: 21.981

10.  The importance of data source in prescription drug monitoring program research.

Authors:  Jill R Horwitz; Corey Davis; Lynn McClelland; Rebecca Fordon; Ellen Meara
Journal:  Health Serv Res       Date:  2020-09-02       Impact factor: 3.402

View more
  8 in total

1.  The effect of state policies on rates of high-risk prescribing of an initial opioid analgesic.

Authors:  Bradley D Stein; Flora Sheng; Erin A Taylor; Andrew W Dick; Mark Sorbero; Rosalie Liccardo Pacula
Journal:  Drug Alcohol Depend       Date:  2021-12-28       Impact factor: 4.492

2.  Association of prescription drug monitoring program laws with bedridden and missed work days.

Authors:  Martha Wetzel; Courtney R Yarbrough; Silke A von Esenwein; Jason M Hockenberry
Journal:  Health Serv Res       Date:  2021-08-19       Impact factor: 3.402

3.  Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin.

Authors:  Julia Dickson-Gomez; Erika Christenson; Margaret Weeks; Carol Galletly; Jennifer Wogen; Antoinette Spector; Madelyn McDonald; Jessica Ohlrich
Journal:  Subst Abuse       Date:  2021-03-25

4.  Certificate-of-need laws and substance use treatment.

Authors:  James Bailey; Thanh Lu; Patrick Vogt
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-05-18

5.  The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis.

Authors:  Julia Dickson-Gomez; Sarah Krechel; Antoinette Spector; Margaret Weeks; Jessica Ohlrich; H Danielle Green Montaque; Jianghong Li
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-07-21

6.  The importance of data source in prescription drug monitoring program research.

Authors:  Jill R Horwitz; Corey Davis; Lynn McClelland; Rebecca Fordon; Ellen Meara
Journal:  Health Serv Res       Date:  2020-09-02       Impact factor: 3.402

7.  Good Samaritan laws and overdose mortality in the United States in the fentanyl era.

Authors:  Leah Hamilton; Corey S Davis; Nicole Kravitz-Wirtz; William Ponicki; Magdalena Cerdá
Journal:  Int J Drug Policy       Date:  2021-06-03

8.  Spatiotemporal Analysis of the Association Between Pain Management Clinic Laws and Opioid Prescribing and Overdose Deaths.

Authors:  Magdalena Cerdá; Katherine Wheeler-Martin; Emilie Bruzelius; William Ponicki; Paul Gruenewald; Christine Mauro; Stephen Crystal; Corey S Davis; Katherine Keyes; Deborah Hasin; Kara E Rudolph; Silvia S Martins
Journal:  Am J Epidemiol       Date:  2021-12-01       Impact factor: 5.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.